HLS Therapeutics, Inc. · TSX:HLS
HLS Therapeutics — Q3 2026 Earnings Presentation
21 slides from HLS Therapeutics's earnings presentation, Nov 12, 2026
Slide 1: Q3 2026 Earnings Call – November 12, 2026
Q3 2026 Earnings Call – November 12, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation are “forward-looking statements”. Any statements contained in this presentation. These factors should be considered statements that express or involve discussions with respect to predictions, carefully and prospective investors shoul
Slide 3: Q3 Big Picture
Q3 Big Picture 01 02 03 CV growth engine Increasing CV portfolio Expanding the CV accelerating profitability franchise into heart failure (VERQUVO) Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results m
Slide 4: Cardiovascular Portfolio Growth Accelerating
Cardiovascular Portfolio Growth Accelerating Cardiovascular portfolio net sales growth (millions) CAD Private coverage for Third quarter Year to date NILEMDO now in effect for Vascepa NILEMDO ~80% of privately insured 8 22 Canadians 20 7 18 6 21% 16 19% 5 14 12 4 10 3 8 pCPA negotiations for 2 6 pub
Slide 5: Toronto Stock Exchange (TSX) - HLS HLS THERAPEUTICS INC.
Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update HLS THERAPEUTICS INC. 5
Slide 6: Balanced Capital Allocation
Balanced Capital Allocation 01 02 03 Investing Returning Debt in growth capital repayment Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update HLS T
Slide 7: Building Momentum, Accelerating Growth
2026 2027 Building Momentum Accelerating Growth $56–60M $18.5–21M Step-up in revenue and Adj. EBITDA growth 2026 Revenue 2026 Adj. EBITDA Further acceleration in 2028 Expect around the midpoint Expect lower half of range Upcoming catalysts NEXLIZET Mid single-digit growth Continued investment in app
Slide 8: An Increasingly Diversified Portfolio
An Increasingly Diversified Portfolio NILEMDO / NEXLIZET® new product launches Growing VASCEPA® and VERQUVO ® Stable CLOZARIL® base Illustrative purposes only; not financial guidance Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-l
Slide 9: Four CV Medicines, One Goal
Four CV Medicines, One Goal Reducing Cardiovascular Risk for Canadians VASCEPA® NILEMDO NEXLIZET®* VERQUVO® First/only in Well-tolerated, Large outcomes trials Many years of real- Integrated into global Go-to-market class medicines all oral portfolio demonstrated CV world evidence treatment guidelin
Slide 10: Continued Prescribing Growth (VASCEPA)
VASCEPA® TRx Units (thousands) Since Launch - Canada Continued 200 180 Prescribing 160 140 +16% units Growth YTD 2026 vs YTD 2025 120 100 80 60 Patent protection +12% net sales 40 through the late YTD 2026 vs YTD 2025* 20 2030’s 0 2020 2021 2022 2023 2024 2025 TTM 09.30.26 * in Canadian dollars Toro
Slide 11: NILEMDO: Launch Ramping as Private Coverage Takes Effect
NILEMDO : Launch Ramping as Private Coverage Takes Effect NILEMDO net sales +91% (thousands) CAD vs Q2 1,700 >3x new patients in Q3 Vascepa's new-patient Up from 1,200 initiated through pace C$817K the end of Q2 At the same point in its launch C$427K ~1 in 5 >80% target prescribers have of privately
Slide 12: Momentum Building with Key Upcoming CV Catalysts
Momentum Building with Key Upcoming CV Catalysts Q3 2026 Q4 2026 Q4 2026 Q1 2027 H1 2027 H1 2027 ✓ NILEMDO Private pCPA Negotiations to NEXLIZET Health VERQUVO Launch NILEMDO Public NEXLIZET Launch2 Coverage in Place Begin Canada Decision Begins Listings ~80% of eligible privately Following CDA-AMC
Slide 13: VERQUVO: Extending Our CV Franchise into Heart Failure
VERQUVO®: Extending Our CV Franchise into Heart Failure HOW WE'LL GO TO MARKET Current CV portfolio VASCEPA® · NILEMDO · NEXLIZET® Starting Q1 2027 Lipid management and CV risk Chronic heart failure (HFrEF) after 1 Medical-led Focus reduction a recent worsening event¹ Medical team focuses on top hea
Slide 14: National patient volumes grew sequentially each month in Q3
National patient volumes grew sequentially each month in Q3 Patient growth coming from Western Canada (BC, Alberta, Saskatchewan) ~97% annual patient retention on branded Clozaril in Quebec Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains fo
Slide 15: Q3 2026 Financial Review
Q3 2026 Financial Review Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update HLS THERAPEUTICS INC. 15
Slide 16: Cardiovascular Now ~Half of Canadian Product Sales
Cardiovascular Now ~Half of Canadian Product Sales Share of Canadian product sales, third quarter CAD, net sales Q3 revenue, up 5% year $14.2M over year Year to date $41.7M, up 3% CV portfolio net sales 43% 48% +21% growth in Q3 Up 19% year to date (local currency) Canadian product sales Q3 2025 Q3
Slide 17: Adjusted EBITDA Improving as Cardiovascular Turns Profitable
Adjusted EBITDA Improving as Cardiovascular Turns Profitable CV portfolio direct brand contribution to Adj. EBITDA $5.0M (millions) USD Q3 Adj. EBITDA, up from $4.9M in Q3 2025 Breakeven $0.7M And up from $4.7M in Q2 2026; margins improving H1 2026 Q3 2026 Including NILEMDO launch Turned positive in
Slide 18: Growing Cash Generation Driven by Product Performance and Declining Debt
Growing Cash Generation Driven by Product Performance and Declining Debt Presented on Trailing Twelve Months Basis – USD in millions $16 $15.3 $14 $12 $10 $8.1 $8 $6 $4 $2.3 $2.7 $2 $- Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 TTM AEBITDA ex-royalty reve
Slide 19: Stronger Financials Fund Growth and Shareholder Value
Stronger Financials Fund Growth and Shareholder Value 01 02 03 Investing in Growth Returning Capital Debt Repayment Pursuing BD opportunities aligned with NCIB expanded in September to 1.9M $1.1M principal repayment in Q3 strategic focus, capabilities and resources shares Term loan $41.3M, down 17%
Slide 20: HLS: A Fundamentally Stronger Company
HLS: A Fundamentally Stronger Company 01 02 03 Strengthened Growth Engine Catalysts Ahead Operations & Financials Delivering Strongest balance sheet in years CV portfolio grew 21% vs prior year NILEMDO public listings expected H1’27 Robust cash generation NILEMDO grew 91% sequentially from Q2 NEXLIZ
Slide 21: Q3 2026 Earnings Call – November 12, 2026
Q3 2026 Earnings Call – November 12, 2026